Palatin Technologies, Inc. Reports Positive Data From An At Home Study Of Pre And Postmenopausal Women With Female Sexual Arousal Disorder
Sep 28th 2007Drug InformationSexual Health
Palatin Technologies, Inc. (Amex: PTN) announced positive results from an at home Phase 2 trial evaluating bremelanotide for the treatment of female sexual arousal disorder (FSAD). The objective of this exploratory study was to identify potential efficacy endpoints for future studies and to evaluate the safety of intranasal (IN) bremelanotide, relative to placebo and under the conditions of home use, for the treatment of FSAD in pre and postmenopausal women. [click link for full article]
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
